CA3195133A1 - Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride - Google Patents
Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochlorideInfo
- Publication number
- CA3195133A1 CA3195133A1 CA3195133A CA3195133A CA3195133A1 CA 3195133 A1 CA3195133 A1 CA 3195133A1 CA 3195133 A CA3195133 A CA 3195133A CA 3195133 A CA3195133 A CA 3195133A CA 3195133 A1 CA3195133 A1 CA 3195133A1
- Authority
- CA
- Canada
- Prior art keywords
- dexmedetomidine
- pharmaceutically acceptable
- subject
- acceptable salt
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089135P | 2020-10-08 | 2020-10-08 | |
| US63/089,135 | 2020-10-08 | ||
| PCT/US2021/054171 WO2022076818A1 (en) | 2020-10-08 | 2021-10-08 | Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3195133A1 true CA3195133A1 (en) | 2022-04-14 |
Family
ID=81126063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3195133A Pending CA3195133A1 (en) | 2020-10-08 | 2021-10-08 | Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240024289A1 (https=) |
| EP (1) | EP4225305A4 (https=) |
| JP (1) | JP2023545372A (https=) |
| KR (1) | KR20230084186A (https=) |
| CN (1) | CN116615243A (https=) |
| AU (1) | AU2021356687A1 (https=) |
| CA (1) | CA3195133A1 (https=) |
| IL (1) | IL301971A (https=) |
| MX (1) | MX2023003993A (https=) |
| TW (1) | TW202228682A (https=) |
| WO (1) | WO2022076818A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL267689B2 (en) | 2016-12-31 | 2025-05-01 | Bioxcel Therapeutics Inc | Use of sublingual dexmedetomidine for the treatment of agitation |
| BR112020026672A2 (pt) | 2018-06-27 | 2021-03-30 | Bioxcel Therapeutics, Inc. | Formulações de filme contendo dexmedetomidina e métodos para produzi-las |
| BR112022000992A2 (pt) | 2019-07-19 | 2022-06-14 | Arx Llc | Regimes de tratamento de dexmedetomidina não sedantes |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8242158B1 (en) * | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
| CA2884926C (en) * | 2012-10-15 | 2021-09-21 | Orion Corporation | A veterinary method of alleviating noise aversion |
| KR101881791B1 (ko) * | 2013-10-07 | 2018-07-25 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물 |
| IL267689B2 (en) * | 2016-12-31 | 2025-05-01 | Bioxcel Therapeutics Inc | Use of sublingual dexmedetomidine for the treatment of agitation |
| BR112022000992A2 (pt) * | 2019-07-19 | 2022-06-14 | Arx Llc | Regimes de tratamento de dexmedetomidina não sedantes |
-
2021
- 2021-10-08 US US18/030,405 patent/US20240024289A1/en active Pending
- 2021-10-08 TW TW110137597A patent/TW202228682A/zh unknown
- 2021-10-08 AU AU2021356687A patent/AU2021356687A1/en not_active Abandoned
- 2021-10-08 IL IL301971A patent/IL301971A/en unknown
- 2021-10-08 CN CN202180069020.2A patent/CN116615243A/zh active Pending
- 2021-10-08 KR KR1020237013556A patent/KR20230084186A/ko not_active Withdrawn
- 2021-10-08 MX MX2023003993A patent/MX2023003993A/es unknown
- 2021-10-08 WO PCT/US2021/054171 patent/WO2022076818A1/en not_active Ceased
- 2021-10-08 EP EP21878615.0A patent/EP4225305A4/en not_active Withdrawn
- 2021-10-08 JP JP2023518752A patent/JP2023545372A/ja active Pending
- 2021-10-08 CA CA3195133A patent/CA3195133A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116615243A (zh) | 2023-08-18 |
| IL301971A (en) | 2023-06-01 |
| MX2023003993A (es) | 2023-05-24 |
| JP2023545372A (ja) | 2023-10-30 |
| WO2022076818A1 (en) | 2022-04-14 |
| EP4225305A1 (en) | 2023-08-16 |
| TW202228682A (zh) | 2022-08-01 |
| US20240024289A1 (en) | 2024-01-25 |
| AU2021356687A9 (en) | 2024-10-03 |
| KR20230084186A (ko) | 2023-06-12 |
| EP4225305A4 (en) | 2024-10-23 |
| AU2021356687A1 (en) | 2023-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11998529B2 (en) | Non-sedating dexmedetomidine treatment regimens | |
| US20240024289A1 (en) | Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride | |
| US20250228833A1 (en) | Methods and compositions for treating agitation | |
| TW202019388A (zh) | 含右美托咪啶(dexmedetomidine)之膜調配物及其製造方法 | |
| US12138247B2 (en) | Non-sedating dexmedetomidine treatment regimens | |
| KR20130099140A (ko) | 베포타스틴 조성물 | |
| CA3224257A1 (en) | Methods for treating depressive states | |
| JP2000095675A (ja) | 口中溶解型又は咀嚼型鼻炎治療用固形内服医薬組成物 | |
| WO2024263973A1 (en) | Dexmedetomidine treatment regimens | |
| CN117750956A (zh) | 用于治疗抑郁状态的方法 | |
| JP2013032408A (ja) | 口中溶解型又は咀嚼型鼻炎治療用固形内服医薬組成物 | |
| EA045213B1 (ru) | Пленочный состав, содержащий дексмедетомидин, и способ его получения | |
| EA040771B1 (ru) | Пленочные составы, содержащие дексмедетомидин, и способы их получения | |
| JP2010150284A (ja) | 口中溶解型又は咀嚼型鼻炎治療用固形内服医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240906 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240906 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240906 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251119 |